NCT06314763View on ClinicalTrials.gov

Rivaroxaban Sotorasib Interaction Study

PHASE4CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

March 21, 2024

Study Completion Date

March 21, 2024

Conditions

Drug Drug Interaction Study

Interventions

DRUG

Rivaroxaban 20mg

Single dose on day 1 and day 16

DRUG

Sotorasib 960mg

Daily dose from day 3 till day 16

Trial Locations (1)

Unknown

Radboud university medical centre, Nijmegen

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Radboud University Medical Center

OTHER